HAROW: the first comprehensive prospective observational study comparing treatment options in localized prostate cancer.
Foundation Men's Health (Stiftung Männergesundheit), Claire-Waldoff-Str. 3, 10117, Berlin, Germany. [email protected]
Foundation Men's Health (Stiftung Männergesundheit), Claire-Waldoff-Str. 3, 10117, Berlin, Germany.
Urological Practice, Langenfeld, Germany.
Department of Urology, Hospital Weiden, Weiden, Germany.
- Published Article
World journal of urology
- Publication Date
Whereas RP remains the main treatment option of localized PCa, active surveillance appears to become an accepted and selectively employed treatment option. Careful selection of patients is documented by the highest proportion of patients with low risk (82.5 %), PSA density <0.2 ng/ml/ml (77.5 %), T1 staging (83.6 %), Gleason score ≤6 (92.5 %), ≤2 positive biopsies (79.4 %), and lowest mean PSA (5.8 ng/ml) in the AS group. The relatively high progression rate in the AS group has to be considered in the context of treatment changes; 71/155 patients had a documented change of treatment and 62 of them with a follow-up period of >3 months.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/26373955